Compare · IART vs MDLN
IART vs MDLN
Side-by-side comparison of Integra LifeSciences Holdings Corporation (IART) and Medline Inc. (MDLN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IART and MDLN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $44.15B, about 33.4x IART ($1.32B).
- MDLN has been more active in the news (20 items in the past 4 weeks vs 7 for IART).
- MDLN has more recent analyst coverage (25 ratings vs 24 for IART).
- Company
- Integra LifeSciences Holdings Corporation
- Medline Inc.
- Price
- -
- -
- Market cap
- $1.32B
- $44.15B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- News (4w)
- 7
- 20
- Recent ratings
- 24
- 25
Integra LifeSciences Holdings Corporation
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. It operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, hydrocephalus management systems, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services. It also sells approximately 40,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute and chronic wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, it offers skin and wound repair, bone and joint fixation implants in the upper and lower extremities, and bone grafts products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.
Latest IART
- SEC Form 4 filed by EVP & Chief Commercial Officer Mcbreen Michael J.
- SEC Form 4 filed by President and CEO Essig Stuart
- The Body as Blueprint: A Recently Public Biotech Bets That Regrown Tissue Beats Replacement Parts
- Integra LifeSciences to Present at the 2026 Jefferies Global Healthcare Conference
- SEC Form SD filed by Integra LifeSciences Holdings Corporation
- Integra upgraded by Citigroup with a new price target
- Regenerative Medicine's Newest Public Company Is Building Tissue, Not Replacing It
- Director Hill Barbara B was granted 24,338 shares, increasing direct ownership by 19% to 151,191 units (SEC Form 4)
- Director Bradley Keith covered exercise/tax liability with 882 shares, decreasing direct ownership by 0.99% to 88,254 units (SEC Form 4)
- SEC Form 4 filed by Director Clay Shaundra
Latest MDLN
- Medline Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Entry into a Material Definitive Agreement
- Large owner Hellman & Friedman Capital Partners X (Parallel), L.P. sold $1,164,385,709 worth of shares (31,868,237 units at $36.54) and disposed of 1,887,801 shares (SEC Form 4)
- Director Healy Patrick J acquired 202,106 shares, increasing direct ownership by 15% to 1,387,921 units (SEC Form 4)
- Large owner Bx Mozart Ml-2 Holdco L.P. sold $1,217,349,994 worth of shares (33,317,824 units at $36.54) and disposed of 438,214 shares (SEC Form 4)
- Large owner Bcp 8 Holdings Mozart Manager L.L.C. sold $1,217,349,994 worth of shares (33,317,824 units at $36.54) and disposed of 438,214 shares (SEC Form 4)
- Medline's Prime Vendor model expands outside the United States
- Medline Inc. announces closing of upsized secondary offering of Class A common stock
- Medline announces participation in upcoming investor conferences
- MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update
- Large owner Bx Mozart Ml-1 Holdco L.P. converted options into 11,348,698 shares and disposed of 11,348,698 units of Class B Common Stock (SEC Form 4)